1、 李祥芳,田平.临床药师参与抗肿瘤药物治疗与安全管理的实践与研究[J].临床合理用药杂志,2019,12(30):113-114. 李祥芳,田平.临床药师参与抗肿瘤药物治疗与安全管理的实践与研究[J].临床合理用药杂志,2019,12(30):113-114.
2、 CAPPUZZO F,MORO-SIBILOT D,GAUTSCHI O,et al.Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma:An expert consensus[J].Lung Cancer,2015,87(2):89-95. CAPPUZZO F,MORO-SIBILOT D,GAUTSCHI O,et al.Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma:An expert consensus[J].Lung Cancer,2015,87(2):89-95.
3、 王可,李娟,孙建国,等.间变性淋巴瘤激酶抑制剂不良反应管理西南专家建议(2021年版)[J].中国肺癌杂志,2021,24(12):815-828. 王可,李娟,孙建国,等.间变性淋巴瘤激酶抑制剂不良反应管理西南专家建议(2021年版)[J].中国肺癌杂志,2021,24(12):815-828.
4、 SOLOMON B J,MOK T,KIM D W,et al.First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J].N Engl J Med,2014,371(23):2167-2177. SOLOMON B J,MOK T,KIM D W,et al.First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J].N Engl J Med,2014,371(23):2167-2177.
5、 SHI Y,CHEN G,WANG X,et al.Furmonertinib(AST2818)versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer(FURLONG):A multicentre,double-blind,randomised phase 3 study[J].Lancet Respir Med,2022,10(11):1019-1028. SHI Y,CHEN G,WANG X,et al.Furmonertinib(AST2818)versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer(FURLONG):A multicentre,double-blind,randomised phase 3 study[J].Lancet Respir Med,2022,10(11):1019-1028.
6、 LU S,DONG X,JIAN H,et al.AENEAS:A Randomized Phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or MetastaticNon-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations[J].J Clin Oncol,2022,40(27):3162-3171. LU S,DONG X,JIAN H,et al.AENEAS:A Randomized Phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or MetastaticNon-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations[J].J Clin Oncol,2022,40(27):3162-3171.
7、 CHENG Y,HE Y,LI W,et al.Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC:FLAURA China,A randomized study[J].Target Oncol,2021,16(2):165-176. CHENG Y,HE Y,LI W,et al.Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC:FLAURA China,A randomized study[J].Target Oncol,2021,16(2):165-176.
8、 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2022[M].北京:人民卫生出版社,2022:96-97. 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2022[M].北京:人民卫生出版社,2022:96-97.
9、 顾航烨,吕晴,陈永.伏美替尼治疗EGFR基因突变非小细胞肺癌的研究进展[J].中国药房,2023,34(14):1788-1792. 顾航烨,吕晴,陈永.伏美替尼治疗EGFR基因突变非小细胞肺癌的研究进展[J].中国药房,2023,34(14):1788-1792.
10、 付裕豪,邱学佳,李宵,等.第三代EGFR-TKIs在晚期非小细胞肺癌中的遴选量化评估[J].中国医院药学杂志,2023,43(1):21-27. 付裕豪,邱学佳,李宵,等.第三代EGFR-TKIs在晚期非小细胞肺癌中的遴选量化评估[J].中国医院药学杂志,2023,43(1):21-27.
11、 LI M,KROETZ D L.Bevacizumab-induced hypertension:Clinical presentation and molecular understanding[J].Pharmacol Ther,2018(182):152-160. LI M,KROETZ D L.Bevacizumab-induced hypertension:Clinical presentation and molecular understanding[J].Pharmacol Ther,2018(182):152-160.
12、 ZHAO Y Y,XUE C,JIANG W,et al.Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab[J].J Thorac Oncol,2012,7(1):71-75. ZHAO Y Y,XUE C,JIANG W,et al.Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab[J].J Thorac Oncol,2012,7(1):71-75.
13、 宁丽娜,杜敏娟,李立丰.非小细胞肺癌分子靶向治疗的研究进展[J].中国现代药物应用,2021,15(8):241-243. 宁丽娜,杜敏娟,李立丰.非小细胞肺癌分子靶向治疗的研究进展[J].中国现代药物应用,2021,15(8):241-243.
